HPLC Purity Control of Final Compounds
Purity of compounds 1 to 28 was determined using LC/MS as follows: The Surveyor®-LC-system consisted of a lamp, an autosampler, and a PDA detector. Mass spectrometry was performed on a Surveyor MSQ plus (ThermoFisher, Dreieich, Germany). The single quadrupole mass spectrometer was equipped with an electrospray interface (ESI). The system was operated by the standard software Xcalibur®.
A RP C18 NUCLEODUR® 100-5 (3 mm) column (Macherey-Nagel GmbH, Düren, Germany) was used as stationary phase. All solvents were HPLC grade.
Solvent system:
In a gradient run the percentage of acetonitrile (containing 0.1% TFA) was increased from an initial concentration of 5% at 0 min to 100% for 5 min.
The injection volume was 10µL and flow rate was set to 800 µL/min. Ms analysis was carried out with a capillary temperature of 350 o C and CID of 75 V. Spectra were acquired in positive ionization mode from 100 to 1000 m/z and 254 nm UV-mode.
In both cases the injection volume was 5 µL and flow rate was set to 350 µL/min. MS analysis was carried out at a spray voltage of 3800 V, a capillary temperature of 350 o C and a source CID of 10 V. Spectra were acquired in positive ionization mode from 100 to 1000 m/z and full scan UV-mode. 61, 154.12, 142.57, 140.85, 137.61, 135.04, 134.03, 132.94, 131.31, 130.45, 129.41, 128.31, 127.24, 125.77 12, 166.67, 154.02, 142.74, 139.32, 137.41, 134.07, 133.62, 131.63, 130.44, 130.26, 130.01, 127.17, 125.62, 52.76 93, 159.43, 153.77, 141.55, 139.04, 138.89, 136.75, 136.13, 134.35, 133.25, 130.19, 129.63, 129.21, 127.21, 125.94, 125.03, 124.11, 121.92, 118.74, 115.25, 112.57, 63.64, 14.78; MS (ESI): 463.92 (M+H) + . N- (3) (4) (5) 73, 166.22, 159.67, 153.72, 142.17, 138.98, 138.45, 136.49, 134.81, 134.74, 132.34, 130.41, 129.53, 129.11, 127.36, 125.36, 124.45, 124.20, 121.07, 119.00, 115.48, 112.74, 63.87, 15.04; MS (ESI): 428.84 (M+H) + . N- (3) (4) (5) 16, 164.15, 160.65, 153.66, 142.81, 139.69, 139.31, 136.96, 135.31, 132.29, 131.30, 130.51, 130.21, 125.57, 125.55, 125.10, 121.71, 119.35, 116.29, 115.19, 112.98, 64.30, 56.13, 15.08 01, 159.44, 154.27, 141.21, 140.74, 139.20, 136.42, 136.34, 136.23, 134.20, 131.16, 130.79, 130.27, 130.23, 129.82, 126.56, 125.24, 124.26, 122.17, 118.77, 116.98, 115.39, 113.75, 112.58, 63.66, 14.78 
Comd

N-(3-(5-(3-Ethoxyphenyl)-thiophene-2-yl-carbonyl)phenyl)-isophthalamic acid methyl ester (15):
purified by CC (hexane/ethyl acetate 85:15); yield: 78 % (370 mg; white solid; mp. 138-9 o C). 
13
C NMR (CDCl 3 ) δ 187. 47, 166.17, 165.02, 159.40, 153.52, 141.82, 138.67, 138.08, 136.28, 134.91, 134.42, 132.88, 132.03, 130.65, 130.14, 129.27, 129.13, 127.78, 125.26, 124.18, 124.09, 120.98, 118.72, 115.23, 112.45, 63.60, 52.42, 14.78 45, 157.00, 152.95, 147.30, 133.85, 132.50, 129.90, 129.55, 129.50, 129.30, 126.40, 126.15, 126.00, 119.35, 118.65, 115.30 50, 145.05, 143.40, 142.95, 135.50, 130.45, 129.85, 128.10, 127.30, 126.10, 123.80, 120.65, 116.45, 116.35, 114.35, 36.70 77, 159.63, 153.06, 142.20, 141.93, 139.32, 135.95, 133.57, 129.40, 129.35, 127.54, 125.55, 124.72, 124.00, 121.64, 118.54, 113.73, 64.90, 55.47 61, 159.70, 159.07, 153.52, 142.91, 140.37, 138.11, 137.04, 135.42, 131.38, 130.61, 129.40, 128.84, 128.53, 125.30, 122.37, 120.20, 118.45, 117.27, 115.62, 113.84, 70.73 71, 158.80, 158.75, 152.51, 142.12, 139.34, 137.27, 136.15, 134.52, 130.49, 129.81, 121.44, 119.32, 118.40, 116.54, 114.61, 113.52, 69.83, 69.74, 21.42 61, 160.94, 159.70, 153.42, 143.01, 140.34, 138.11, 136.92, 135.43, 131.37, 130.62, 129.45, 128.81, 128.50, 125.64, 122.33, 120.22, 119.47, 116.38, 115.55, 113.04, 75.14, 70.72, 29.13, 19.57 81, 160.94, 158.51, 153.32, 143.22, 140.35, 136.87, 135.42, 131.34, 130.68, 125.53, 121.18, 120.35, 119.34, 116.32, 113.01, 75.10, 29.14, 19.52 H NMR (CD 3 OD) δ 7.60 (d, J = 4.0 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.29 -7.25 (m, 1H), 7.22 -7.17 (m, 3H), 7.05 (ddd, J = 8.1, 2.5, 1.1 Hz, 1H), 6.91 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 6.88 -6.85 (m, 1H), 6.77 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H); 13 C NMR (CD 3 OD) δ 188. 97, 159.59, 158.92, 147.64, 146.28, 140.15, 137.06, 137.00, 133.34, 131.50, 130.78, 122.64, 121.32, 120.80, 118.28, 116.50, 116.49 2H), 7.75 (d, J = 3.9 Hz, 1H), 7.45 (d, J = 3.9 Hz, 1H), 2H) , 4.14 (s, 3H); 13 C NMR (CDCl 3 ) δ 185. 80, 162.10, 144.02, 137.59, 133.23, 130.55, 125.10, 113.75, sulfanylthiophen-2-yl)methanone (27a): purified by CC (hexane/ethyl acetate 99:1); yield 90 % (322 mg; brown oil). 1 H NMR (CDCl 3 ) δ 8. 2H), 7.78 (d, J = 3.9 Hz, 1H), 1H), 7.41 (d, J = 3.9 Hz, 1H), 2H), 7.21 (dt, J = 7.6, 1.9 Hz, 2H), 7.08 (ddd, J = 8.3, 2.5, 0.8 Hz, 1H) , 4.14 (s, 3H), 4.04 (s, 3H); 13 C NMR (CDCl 3 ) δ 185. 84, 163.18, 160.16, 146.00, 143.97, 136.55, 134.24, 132.43, 131.50, 130.28, 130.19, 122.40, 115.62, 113.75, 113.55, 55.48, sulfanylthiophen-2-yl)methanone (27): purified by CC (dichloromethane/methanol 99:1); yield 69 % (190 mg; yellow oil).
(3-(Benzyloxy)phenyl)(5-(3-isobutoxyphenyl)thiophen-2-yl)methanone
1
H NMR (CD 3 OD) δ 7. 1H), 1H), 7.53 (d, J = 3.9 Hz, 1H), 2H), 1H), 1H), 6.86 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H), 1H), 6.73 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H); 13 C NMR (CD 3 OD) δ 187. 86, 163.59, 159.47, 146.94, 145.93, 137.47, 136.20, 133.80, 133.03, 131.47, 129.96, 122.34, 117.94, 116.44, 116.28 49, 164.27, 159.84, 151.51, 150.11, 143.49, 134.41, 134.28, 133.36, 132.01, 129.13, 122.31, 119.37, 116.57, 114.87 Preparation of human 17β-HSD1 and 17β-HSD2. Human 17β-HSD1 and 17β-HSD2 were obtained from human placenta according to previously described procedures. [1] Fresh human placenta was homogenized, and cytosolic fraction and microsomes were separated by fractional centrifugation. For the partial purification of 17β-HSD1, the cytosolic fraction was precipitated with ammonium sulfate. 17β-HSD2 was obtained from the microsomal fraction.
3.2.
Inhibition of human 17β-HSD1. Inhibitory activities were evaluated by an established method with minor modifications. [1] Briefly, the enzyme preparation was incubated with NADH (500 µM) in the presence of potential inhibitors at 37 o C in a phosphate buffer (50 mM) supplemented with 20% of glycerol and EDTA (1 mM). Inhibitor stock solutions were prepared in DMSO. The final concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was started by addition of a mixture of unlabelled-and [2, 4, 6, H]-E1 (final concentration: 500 nM, 0.15 µCi). After 10 min, the incubation was stopped with HgCl 2 and the mixture was extracted with diethylether. After evaporation, the steroids were dissolved in acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 reverse phase chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a HPLC-system (Agilent 1200 Series, Agilent Technologies, Waldbronn). Detection and quantification of the steroids were performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The conversion rate was calculated after analysis of the resulting chromatograms according to the following equation: %conversion = [%E2/(%E2 + %E1)]x100
Each value was calculated from at least three independent experiments.
3.3.
Inhibition of human 17β-HSD2. The h17β-HSD2 inhibition assay was performed similarly to the h17β-HSD1 procedure. The microsomal fraction was incubated with NAD + [1500 µM], test compound and a mixture of unlabelled-and [2, 4, 6, H]-E2 (final concentration: 500 nM, 0.11 µCi) for 20 min at 37 o C. Further treatment of the samples and HPLC separation was carried out as mentioned above.
The conversion rate was calculated after analysis of the resulting chromatograms according to the following equation: %conversion = [%E1/(%E1 + %E2)]x100
3.4.
Preparation of murine 17β-HSD1. Recombinant mouse 17β-HSD1 enzyme was produced by transfection of HEK 293 cells with a mouse 17β-HSD1 expression plasmid (coding sequence of NM_010475 in pCMV6Entry vector, OriGene Technologies, Inc.). 48 hours after transfection cells were homogenized by sonication (3 x 10 s) in a buffer containing saccharose (40 mM Tris, S8
